{"pmid":32327904,"pmcid":"PMC7167410","title":"SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant.","text":["SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant.","The current pandemic due to the severe acute respiratory syndrome coronavirus 2 has caused an extreme burden for health care systems globally, and the number of cases is expected to continue to increase, at least in the immediate future. The virus is estimated to have infected more than 1.5 million individuals. The available reports suggest that gastrointestinal (GI) involvement in coronavirus disease 2019 (COVID-19) is common and in some cases the GI symptoms may precede the respiratory symptoms. In addition to direct effects of severe acute respiratory syndrome coronavirus 2, the infected patients remain at risk for the complications commonly managed by gastroenterology and hepatology consultants. The most commonly reported GI manifestation of COVID-19 is diarrhea, which is reported in a third to up to more than half of the patients. Mild to moderate elevation of the liver enzymes are also common, although no case of acute liver failure has been reported so far. Many of the medications used for treatment of COVID-19 can also be associated with GI symptoms or liver injury and can be included in the differential diagnosis in these patients. Although the diagnosis of the infection is currently based on RNA analysis in respiratory samples, the available literature on fecal shedding of this virus suggests that fecal RNA testing might prove to be a useful diagnostic test. It is reasonable to delay all non-urgent endoscopic procedures during the peak of the pandemic and use additional protective equipment such as N95 respirators during endoscopy while most patients can be considered high risk for having been exposed to the virus.","World J Gastroenterol","Hajifathalian, Kaveh","Mahadev, Srihari","Schwartz, Robert E","Shah, Shawn","Sampath, Kartik","Schnoll-Sussman, Felice","Brown, Robert S Jr","Carr-Locke, David","Cohen, David E","Sharaiha, Reem Z","32327904"],"abstract":["The current pandemic due to the severe acute respiratory syndrome coronavirus 2 has caused an extreme burden for health care systems globally, and the number of cases is expected to continue to increase, at least in the immediate future. The virus is estimated to have infected more than 1.5 million individuals. The available reports suggest that gastrointestinal (GI) involvement in coronavirus disease 2019 (COVID-19) is common and in some cases the GI symptoms may precede the respiratory symptoms. In addition to direct effects of severe acute respiratory syndrome coronavirus 2, the infected patients remain at risk for the complications commonly managed by gastroenterology and hepatology consultants. The most commonly reported GI manifestation of COVID-19 is diarrhea, which is reported in a third to up to more than half of the patients. Mild to moderate elevation of the liver enzymes are also common, although no case of acute liver failure has been reported so far. Many of the medications used for treatment of COVID-19 can also be associated with GI symptoms or liver injury and can be included in the differential diagnosis in these patients. Although the diagnosis of the infection is currently based on RNA analysis in respiratory samples, the available literature on fecal shedding of this virus suggests that fecal RNA testing might prove to be a useful diagnostic test. It is reasonable to delay all non-urgent endoscopic procedures during the peak of the pandemic and use additional protective equipment such as N95 respirators during endoscopy while most patients can be considered high risk for having been exposed to the virus."],"journal":"World J Gastroenterol","authors":["Hajifathalian, Kaveh","Mahadev, Srihari","Schwartz, Robert E","Shah, Shawn","Sampath, Kartik","Schnoll-Sussman, Felice","Brown, Robert S Jr","Carr-Locke, David","Cohen, David E","Sharaiha, Reem Z"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327904","week":"202017|Apr 20 - Apr 26","doi":"10.3748/wjg.v26.i14.1546","keywords":["covid-19","gastroenterology","hepatology","liver","sars-cov-2"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664996914785943552,"score":8.518259,"similar":[{"pmid":32213556,"pmcid":"PMC7133387","title":"Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms.","text":["Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms.","OBJECTIVE: The SARS-CoV-2-infected disease (COVID-19) outbreak is a major threat to human beings. Previous studies mainly focused on Wuhan and typical symptoms. We analysed 74 confirmed COVID-19 cases with GI symptoms in the Zhejiang province to determine epidemiological, clinical and virological characteristics. DESIGN: COVID-19 hospital patients were admitted in the Zhejiang province from 17 January 2020 to 8 February 2020. Epidemiological, demographic, clinical, laboratory, management and outcome data of patients with GI symptoms were analysed using multivariate analysis for risk of severe/critical type. Bioinformatics were used to analyse features of SARS-CoV-2 from Zhejiang province. RESULTS: Among enrolled 651 patients, 74 (11.4%) presented with at least one GI symptom (nausea, vomiting or diarrhoea), average age of 46.14 years, 4-day incubation period and 10.8% had pre-existing liver disease. Of patients with COVID-19 with GI symptoms, 17 (22.97%) and 23 (31.08%) had severe/critical types and family clustering, respectively, significantly higher than those without GI symptoms, 47 (8.14%) and 118 (20.45%). Of patients with COVID-19 with GI symptoms, 29 (39.19%), 23 (31.08%), 8 (10.81%) and 16 (21.62%) had significantly higher rates of fever >38.5 degrees C, fatigue, shortness of breath and headache, respectively. Low-dose glucocorticoids and antibiotics were administered to 14.86% and 41.89% of patients, respectively. Sputum production and increased lactate dehydrogenase/glucose levels were risk factors for severe/critical type. Bioinformatics showed sequence mutation of SARS-CoV-2 with m(6)A methylation and changed binding capacity with ACE2. CONCLUSION: We report COVID-19 cases with GI symptoms with novel features outside Wuhan. Attention to patients with COVID-19 with non-classic symptoms should increase to protect health providers.","Gut","Jin, Xi","Lian, Jiang-Shan","Hu, Jian-Hua","Gao, Jianguo","Zheng, Lin","Zhang, Yi-Min","Hao, Shao-Rui","Jia, Hong-Yu","Cai, Huan","Zhang, Xiao-Li","Yu, Guo-Dong","Xu, Kai-Jin","Wang, Xiao-Yan","Gu, Jue-Qing","Zhang, Shan-Yan","Ye, Chan-Yuan","Jin, Ci-Liang","Lu, Ying-Feng","Yu, Xia","Yu, Xiao-Peng","Huang, Jian-Rong","Xu, Kang-Li","Ni, Qin","Yu, Cheng-Bo","Zhu, Biao","Li, Yong-Tao","Liu, Jun","Zhao, Hong","Zhang, Xuan","Yu, Liang","Guo, Yong-Zheng","Su, Jun-Wei","Tao, Jing-Jing","Lang, Guan-Jing","Wu, Xiao-Xin","Wu, Wen-Rui","Qv, Ting-Ting","Xiang, Dai-Rong","Yi, Ping","Shi, Ding","Chen, Yanfei","Ren, Yue","Qiu, Yun-Qing","Li, Lan-Juan","Sheng, Jifang","Yang, Yida","32213556"],"abstract":["OBJECTIVE: The SARS-CoV-2-infected disease (COVID-19) outbreak is a major threat to human beings. Previous studies mainly focused on Wuhan and typical symptoms. We analysed 74 confirmed COVID-19 cases with GI symptoms in the Zhejiang province to determine epidemiological, clinical and virological characteristics. DESIGN: COVID-19 hospital patients were admitted in the Zhejiang province from 17 January 2020 to 8 February 2020. Epidemiological, demographic, clinical, laboratory, management and outcome data of patients with GI symptoms were analysed using multivariate analysis for risk of severe/critical type. Bioinformatics were used to analyse features of SARS-CoV-2 from Zhejiang province. RESULTS: Among enrolled 651 patients, 74 (11.4%) presented with at least one GI symptom (nausea, vomiting or diarrhoea), average age of 46.14 years, 4-day incubation period and 10.8% had pre-existing liver disease. Of patients with COVID-19 with GI symptoms, 17 (22.97%) and 23 (31.08%) had severe/critical types and family clustering, respectively, significantly higher than those without GI symptoms, 47 (8.14%) and 118 (20.45%). Of patients with COVID-19 with GI symptoms, 29 (39.19%), 23 (31.08%), 8 (10.81%) and 16 (21.62%) had significantly higher rates of fever >38.5 degrees C, fatigue, shortness of breath and headache, respectively. Low-dose glucocorticoids and antibiotics were administered to 14.86% and 41.89% of patients, respectively. Sputum production and increased lactate dehydrogenase/glucose levels were risk factors for severe/critical type. Bioinformatics showed sequence mutation of SARS-CoV-2 with m(6)A methylation and changed binding capacity with ACE2. CONCLUSION: We report COVID-19 cases with GI symptoms with novel features outside Wuhan. Attention to patients with COVID-19 with non-classic symptoms should increase to protect health providers."],"journal":"Gut","authors":["Jin, Xi","Lian, Jiang-Shan","Hu, Jian-Hua","Gao, Jianguo","Zheng, Lin","Zhang, Yi-Min","Hao, Shao-Rui","Jia, Hong-Yu","Cai, Huan","Zhang, Xiao-Li","Yu, Guo-Dong","Xu, Kai-Jin","Wang, Xiao-Yan","Gu, Jue-Qing","Zhang, Shan-Yan","Ye, Chan-Yuan","Jin, Ci-Liang","Lu, Ying-Feng","Yu, Xia","Yu, Xiao-Peng","Huang, Jian-Rong","Xu, Kang-Li","Ni, Qin","Yu, Cheng-Bo","Zhu, Biao","Li, Yong-Tao","Liu, Jun","Zhao, Hong","Zhang, Xuan","Yu, Liang","Guo, Yong-Zheng","Su, Jun-Wei","Tao, Jing-Jing","Lang, Guan-Jing","Wu, Xiao-Xin","Wu, Wen-Rui","Qv, Ting-Ting","Xiang, Dai-Rong","Yi, Ping","Shi, Ding","Chen, Yanfei","Ren, Yue","Qiu, Yun-Qing","Li, Lan-Juan","Sheng, Jifang","Yang, Yida"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32213556","week":"202013|Mar 23 - Mar 29","doi":"10.1136/gutjnl-2020-320926","keywords":["diarrhoea","infectious disease"],"source":"PubMed","topics":["Mechanism","Prevention"],"weight":1,"locations":["Wuhan","Zhejiang","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Glucose"],"_version_":1664638838251716608,"score":264.78137},{"pmid":32281689,"title":"COVID-19 and gastrointestinal endoscopies: current insights and emergent strategies.","text":["COVID-19 and gastrointestinal endoscopies: current insights and emergent strategies.","A new coronavirus emerged in December 2019 in Wuhan city of China, named as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and disease was called as coronavirus disease-2019 (COVID-19). The infection due to this virus spread exponentially throughout China and then spread across >205 nations, including the United States (US). Gastrointestinal (GI) endoscopies are routinely performed in the US and globally. Previous reports of isolated infection outbreaks were reported with endoscopes acting as potential vectors. While multidrug-resistant organisms have been reported to be spread by endoscopes, few cases of viruses such as Hepatitis B and C are noted in the literature. COVID-19 predominately spread by droplet transmission, although recent evidence showed that shedding in feces and feco-oral transmission could also be possible. It is unclear if COVID-19 could be transmitted by endoscopes, but it could theoretically happen due to contact with mucous membranes and body fluids. GI endoscopies involve close contact with oral and colonic contents exposing endoscopy staff to respiratory and oropharyngeal secretions. This can increase the risk of contamination and contribute to virus transmission. Given these risks, all major GI societies have called for rescheduling elective non-urgent procedures and perform only emergent or urgent based on the clinical need. Furthermore, pre-screening of all individuals prior to endoscopy is recommended. This article focuses on the risk of COVID-19 transmission by GI shedding, the potential role of endoscopes as a vector of this novel virus including transmission during endoscopies and prevention strategies including deferral of elective non-urgent endoscopy procedures.","Dig Endosc","Perisetti, Abhilash","Gajendran, Mahesh","Boregowda, Umesha","Bansal, Pardeep","Goyal, Hemant","32281689"],"abstract":["A new coronavirus emerged in December 2019 in Wuhan city of China, named as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and disease was called as coronavirus disease-2019 (COVID-19). The infection due to this virus spread exponentially throughout China and then spread across >205 nations, including the United States (US). Gastrointestinal (GI) endoscopies are routinely performed in the US and globally. Previous reports of isolated infection outbreaks were reported with endoscopes acting as potential vectors. While multidrug-resistant organisms have been reported to be spread by endoscopes, few cases of viruses such as Hepatitis B and C are noted in the literature. COVID-19 predominately spread by droplet transmission, although recent evidence showed that shedding in feces and feco-oral transmission could also be possible. It is unclear if COVID-19 could be transmitted by endoscopes, but it could theoretically happen due to contact with mucous membranes and body fluids. GI endoscopies involve close contact with oral and colonic contents exposing endoscopy staff to respiratory and oropharyngeal secretions. This can increase the risk of contamination and contribute to virus transmission. Given these risks, all major GI societies have called for rescheduling elective non-urgent procedures and perform only emergent or urgent based on the clinical need. Furthermore, pre-screening of all individuals prior to endoscopy is recommended. This article focuses on the risk of COVID-19 transmission by GI shedding, the potential role of endoscopes as a vector of this novel virus including transmission during endoscopies and prevention strategies including deferral of elective non-urgent endoscopy procedures."],"journal":"Dig Endosc","authors":["Perisetti, Abhilash","Gajendran, Mahesh","Boregowda, Umesha","Bansal, Pardeep","Goyal, Hemant"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281689","week":"202016|Apr 13 - Apr 19","doi":"10.1111/den.13693","keywords":["covid-19","coronavirus","sars-cov-2","endoscopy","pandemic"],"source":"PubMed","topics":["Transmission","Prevention"],"weight":1,"locations":["Wuhan","China","China","United States","US","US"],"countries":["China","United States"],"countries_codes":["CHN|China","USA|United States"],"_version_":1664636703936086016,"score":252.0536},{"pmid":32202911,"title":"Recommendations by the SEPD and AEG, both in general and on the operation of gastrointestinal endoscopy and gastroenterology units, concerning the current SARS-CoV-2 pandemic (March, 18).","text":["Recommendations by the SEPD and AEG, both in general and on the operation of gastrointestinal endoscopy and gastroenterology units, concerning the current SARS-CoV-2 pandemic (March, 18).","Infection with SARS-CoV-2 coronavirus, and the disease this agent may induce, are a cause of notable concern for the general population and, of course, among our professionals and patients. Gastrointestinal (GI) endoscopy is a high-risk diagnostic-therapeutic procedure in the case of upper GI examinations, and a moderate to low-risk intervention when involving lower GI explorations. The presence of SARS-CoV-2 RNA in the feces of patients infected with the virus, and occasionally in colonic biopsy samples, has been consistently documented. In fact, viral elimination in the feces may be more prolonged than viral identification in respiratory tract secretions. Furthermore, viral transmission may occur in asymptomatic individuals. However, as of this moment no information has been reported on the possibility of viral transmission, even to professionals, via this route.","Rev Esp Enferm Dig","32202911"],"abstract":["Infection with SARS-CoV-2 coronavirus, and the disease this agent may induce, are a cause of notable concern for the general population and, of course, among our professionals and patients. Gastrointestinal (GI) endoscopy is a high-risk diagnostic-therapeutic procedure in the case of upper GI examinations, and a moderate to low-risk intervention when involving lower GI explorations. The presence of SARS-CoV-2 RNA in the feces of patients infected with the virus, and occasionally in colonic biopsy samples, has been consistently documented. In fact, viral elimination in the feces may be more prolonged than viral identification in respiratory tract secretions. Furthermore, viral transmission may occur in asymptomatic individuals. However, as of this moment no information has been reported on the possibility of viral transmission, even to professionals, via this route."],"journal":"Rev Esp Enferm Dig","date":"2020-03-24T11:00:00Z","year":2020,"_id":"32202911","week":"202013|Mar 23 - Mar 29","doi":"10.17235/reed.2020.7052/2020","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664639760427122689,"score":250.61429},{"pmid":32241899,"title":"Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection.","text":["Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection.","OBJECTIVE: To study the GI symptoms in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. DESIGN: We analysed epidemiological, demographic, clinical and laboratory data of 95 cases with SARS-CoV-2 caused coronavirus disease 2019. Real-time reverse transcriptase PCR was used to detect the presence of SARS-CoV-2 in faeces and GI tissues. RESULTS: Among the 95 patients, 58 cases exhibited GI symptoms of which 11 (11.6%) occurred on admission and 47 (49.5%) developed during hospitalisation. Diarrhoea (24.2%), anorexia (17.9%) and nausea (17.9%) were the main symptoms with five (5.3%), five (5.3%) and three (3.2%) cases occurred on the illness onset, respectively. A substantial proportion of patients developed diarrhoea during hospitalisation, potentially aggravated by various drugs including antibiotics. Faecal samples of 65 hospitalised patients were tested for the presence of SARS-CoV-2, including 42 with and 23 without GI symptoms, of which 22 (52.4%) and 9 (39.1%) were positive, respectively. Six patients with GI symptoms were subjected to endoscopy, revealing oesophageal bleeding with erosions and ulcers in one severe patient. SARS-CoV-2 RNA was detected in oesophagus, stomach, duodenum and rectum specimens for both two severe patients. In contrast, only duodenum was positive in one of the four non-severe patients. CONCLUSIONS: GI tract may be a potential transmission route and target organ of SARS-CoV-2.","Gut","Lin, Lu","Jiang, Xiayang","Zhang, Zhenling","Huang, Siwen","Zhang, Zhenyi","Fang, Zhaoxiong","Gu, Zhiqiang","Gao, Liangqing","Shi, Honggang","Mai, Lei","Liu, Yuan","Lin, Xianqi","Lai, Renxu","Yan, Zhixiang","Li, Xiaofeng","Shan, Hong","32241899"],"abstract":["OBJECTIVE: To study the GI symptoms in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. DESIGN: We analysed epidemiological, demographic, clinical and laboratory data of 95 cases with SARS-CoV-2 caused coronavirus disease 2019. Real-time reverse transcriptase PCR was used to detect the presence of SARS-CoV-2 in faeces and GI tissues. RESULTS: Among the 95 patients, 58 cases exhibited GI symptoms of which 11 (11.6%) occurred on admission and 47 (49.5%) developed during hospitalisation. Diarrhoea (24.2%), anorexia (17.9%) and nausea (17.9%) were the main symptoms with five (5.3%), five (5.3%) and three (3.2%) cases occurred on the illness onset, respectively. A substantial proportion of patients developed diarrhoea during hospitalisation, potentially aggravated by various drugs including antibiotics. Faecal samples of 65 hospitalised patients were tested for the presence of SARS-CoV-2, including 42 with and 23 without GI symptoms, of which 22 (52.4%) and 9 (39.1%) were positive, respectively. Six patients with GI symptoms were subjected to endoscopy, revealing oesophageal bleeding with erosions and ulcers in one severe patient. SARS-CoV-2 RNA was detected in oesophagus, stomach, duodenum and rectum specimens for both two severe patients. In contrast, only duodenum was positive in one of the four non-severe patients. CONCLUSIONS: GI tract may be a potential transmission route and target organ of SARS-CoV-2."],"journal":"Gut","authors":["Lin, Lu","Jiang, Xiayang","Zhang, Zhenling","Huang, Siwen","Zhang, Zhenyi","Fang, Zhaoxiong","Gu, Zhiqiang","Gao, Liangqing","Shi, Honggang","Mai, Lei","Liu, Yuan","Lin, Xianqi","Lai, Renxu","Yan, Zhixiang","Li, Xiaofeng","Shan, Hong"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32241899","week":"202014|Mar 30 - Apr 05","doi":"10.1136/gutjnl-2020-321013","keywords":["gastric diseases","gastrointestinal pathology","gastrointestinal tract"],"source":"PubMed","topics":["Diagnosis","Transmission"],"weight":1,"_version_":1664638249400795137,"score":243.45752},{"pmid":32330565,"title":"Donning a new approach to the practice of gastroenterology: perspectives from the COVID-19 pandemic epicenter.","text":["Donning a new approach to the practice of gastroenterology: perspectives from the COVID-19 pandemic epicenter.","The COVID-19 pandemic is seemingly peaking now in New York City and has triggered significant changes to the standard management of gastrointestinal diseases. Priorities such as minimizing viral transmission, preserving (personal protective equipment) PPE, and freeing hospital beds have driven unconventional approaches to managing GI patients. Conversion of endoscopy units to COVID units and redeployment of gastroenterology (GI) fellows and faculty has profoundly changed the profile of most GI services. Meanwhile, consult and procedural volumes have been drastically reduced. In this review we share our collective experiences, how we have changed our practice of medicine, in response to the COVID surge. While we will review our management of specific consults and conditions, the overarching theme focuses primarily on non-invasive measures and maximizing medical therapies. Endoscopic procedures have been reserved for those timely interventions that are most likely to be therapeutic. The role of multidisciplinary discussion, while always important, has now become critical. And the support of our faculty and trainees remains essential. Local leadership can encourage well-being by frequent team check-ins and foster trainee development through remote learning. Advancing a clear vision and a transparent process for how to organize and triage care in the recovery phase will allow for a smooth transition to our \"new normal.\"","Clin Gastroenterol Hepatol","Sethi, Amrita","Swaminath, Arun","Latorre, Melissa","Behin, Daniel S","Jodorkovsky, Daniela","Calo, Delia","Aroniadis, Olga","Mone, Anjali","Mendelsohn, Robin B","Sharaiha, Reem Z","Gonda, Tamas A","Khanna, Lauren G","Bucobo, Juan Carlos","Nagula, Satish","Ho, Sammy","Carr-Locke, David L","Robbins, David H","32330565"],"abstract":["The COVID-19 pandemic is seemingly peaking now in New York City and has triggered significant changes to the standard management of gastrointestinal diseases. Priorities such as minimizing viral transmission, preserving (personal protective equipment) PPE, and freeing hospital beds have driven unconventional approaches to managing GI patients. Conversion of endoscopy units to COVID units and redeployment of gastroenterology (GI) fellows and faculty has profoundly changed the profile of most GI services. Meanwhile, consult and procedural volumes have been drastically reduced. In this review we share our collective experiences, how we have changed our practice of medicine, in response to the COVID surge. While we will review our management of specific consults and conditions, the overarching theme focuses primarily on non-invasive measures and maximizing medical therapies. Endoscopic procedures have been reserved for those timely interventions that are most likely to be therapeutic. The role of multidisciplinary discussion, while always important, has now become critical. And the support of our faculty and trainees remains essential. Local leadership can encourage well-being by frequent team check-ins and foster trainee development through remote learning. Advancing a clear vision and a transparent process for how to organize and triage care in the recovery phase will allow for a smooth transition to our \"new normal.\""],"journal":"Clin Gastroenterol Hepatol","authors":["Sethi, Amrita","Swaminath, Arun","Latorre, Melissa","Behin, Daniel S","Jodorkovsky, Daniela","Calo, Delia","Aroniadis, Olga","Mone, Anjali","Mendelsohn, Robin B","Sharaiha, Reem Z","Gonda, Tamas A","Khanna, Lauren G","Bucobo, Juan Carlos","Nagula, Satish","Ho, Sammy","Carr-Locke, David L","Robbins, David H"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330565","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.cgh.2020.04.032","keywords":["covid-19","consults","experience","guidelines","nysge","ppe"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["New York"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1664996914978881536,"score":240.42017}]}